Cancer Center of the First Hospital, Jilin University, Changchun, China.
Front Immunol. 2022 Jul 11;13:907705. doi: 10.3389/fimmu.2022.907705. eCollection 2022.
Esophageal cancer, as one of the most common malignant tumors in the upper gastrointestinal tract, is highly invasive, with poor prognosis and low 5-year survival rate. Hypopharyngeal cancer has a low incidence among head and neck malignant tumors, but its prognosis is poor and it is prone to recurrence, and because the upper respiratory tract has similar tissue types as the upper gastrointestinal tract, it is prone to the second primary tumor of the upper gastrointestinal tract, however, such patients with double primary carcinoma are uncommon in the clinic, and most of them are already advanced at the time of diagnosis, losing the chance of surgical resection, with poor results and poor prognosis after radiotherapy treatment, therefore, the choice of treatment strategy for such inoperable resectable patients is still a great challenge for clinicians.In this case, we report a patient with a double primary esophageal squamous carcinoma combined with hypopharyngeal squamous carcinoma without family history of tumor, who achieved complete remission after first-line chemotherapy combined with immunotherapy, with both lesions shrinking and the hypopharyngeal tumor disappearing. The survival benefit was ensured at the same time.
食管癌是上消化道最常见的恶性肿瘤之一，具有侵袭性强、预后差、5 年生存率低的特点。下咽癌在头颈部恶性肿瘤中的发病率较低，但预后较差，容易复发，由于上呼吸道与上消化道的组织类型相似，容易发生上消化道第二原发癌，但此类双原发癌患者在临床上并不常见，大多数患者在诊断时已处于晚期，失去手术切除的机会，放疗治疗效果差，预后差，因此，对于此类不可切除的可切除患者的治疗策略选择仍然是临床医生的巨大挑战。在这种情况下，我们报告了一例无肿瘤家族史的食管鳞状细胞癌合并下咽鳞状细胞癌的双原发癌患者，该患者在一线化疗联合免疫治疗后达到完全缓解，食管和下咽肿瘤均缩小，肿瘤消失。同时保证了生存获益。
